Since Rab27a and TRAF3IP2 contribute to exosome release and inflammation, respectively, we hypothesized that targeting Rab27a or TRAF3IP2 will reduce inflammation, tumor formation, growth and metastasis of BC in a preclinical breast xenograft model. Here, TRAF3IP2 is linked to neoplasm.